Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

generics (uk) limited - ezetimibe - tablets - 10 milligram - ezetimibe

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

teva b.v. - ezetimibe - tablet - 10 milligram(s) - other lipid modifying agents; ezetimibe

Malta - Kiingereza - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - ezetimibe, simvastatin - tablet - ezetimibe 10 mg simvastatin 40 mg - lipid modifying agents

Malta - Kiingereza - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - ezetimibe, simvastatin - tablet - ezetimibe 10 mg simvastatin 20 mg - lipid modifying agents

Malta - Kiingereza - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - ezetimibe, simvastatin - tablet - ezetimibe 10 mg simvastatin 40 mg - lipid modifying agents

Malta - Kiingereza - Medicines Authority

zentiva k.s. u kabelovny 130, dolní mecholupy, 102 37 praha 10, czech republic - ezetimibe - tablet - ezetimibe 10 mg - lipid modifying agents

Malta - Kiingereza - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - ezetimibe - tablet - ezetimibe 10 mg - lipid modifying agents

Malta - Kiingereza - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - ezetimibe - tablet - ezetimibe 10 mg - lipid modifying agents

Malta - Kiingereza - Medicines Authority

althera laboratories ltd 1st floor, 9 exchange place, i.f.s.c. dublin 1, ireland - ezetimibe, atorvastatin - film-coated tablet - ezetimibe 10 mg atorvastatin 10 mg - lipid modifying agents

Israeli - Kiingereza - Ministry of Health

taro international ltd, israel - ezetimibe - tablets - ezetimibe 10 mg - ezetimibe - primary hypercholesterolemia: ezetimibe taro administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezetimibe taro administered with a statin are indicated for use in patients with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis). homozygous sitosterolemia (phytosterolemia): ezetimibe taro are indicated for use in patients with homozygous familial sitosterolemia.